Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma
European Journal of Nuclear Medicine and Molecular Imaging · 2024-12 · 52 (1) · 237-246
DOI: 10.1007/s00259-024-06795-7 ↗Kurz gefasst
Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 27.07.2024. Verfasst von Seyedeh Somayyeh Banihashemian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tajrish Sq, Tehran, 19899-34148, Iran. Hauptthemen laut MEDLINE: Sarcoma, Neoplasm Metastasis, Feasibility Studies. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: The unique expression pattern of fibroblast activation protein (FAP) in stromal and tumor cells, particularly in sarcomas, and its absence in normal tissues, have positioned it as a promising theragnostic approach for the detection and treatment of various cancer types. The objective of this prospective study is to assess the feasibility, safety, biodistribution, and therapeutic efficacy of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. PATIENTS AND METHODS: Eight patients with advanced metastatic sarcoma, who were unresectable or had experienced disease recurrence following conventional treatments, underwent PTRT (peptide-targeted radionuclide therapy) using [177Lu]Lu-FAPI-2286. Prior to the treatment, confirmation of tumor uptake was obtained through [68Ga]Ga-FAPI-2286 PET/CT. RESULTS: After four cycles of PTRT with [177Lu]Lu-FAPI-2286 (6660-7400 MBq), with a 6-8-week interval between each cycle, no grade 3 or 4 side effects were observed in the patients, and the treatment was well tolerated by all participants. The results demonstrated a 52.37% reduction in the average volume of the primary tumor, accompanied by a significant decrease in SUVmax and TBR of the metastatic lesions (29.67% and 43.66% respectively), especially in cases of lung metastasis. Furthermore, besides the improvement in physical capacity, there was a noticeable reduction in pain, an increase in overall survival, and enhanced satisfaction with the treatment reported by the patients. CONCLUSION: [177Lu]Lu-FAPI-2286 PTRT, utilized for diverse cancer types, exhibited favorable tolerability in sarcoma patients, with minimal side effects, long-lasting retention of the radiopeptide within the tumor, and promising therapeutic effects. Preliminary findings of this prospective study need to be confirmed through further clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tajrish Sq, Tehran, 19899-34148, Iran.
- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tajrish Sq, Tehran, 19899-34148, Iran. profmeakbari@gmail.com.
- Department of Nuclear Medicine, Shohada'e Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Khatam PET-CT Center, Khatam Hospital, Tehran, Iran.
- Parsisotope Company, Tehran, Iran.
- Department of Cellular and Molecular Biology, School of Biology, Damghan University, Damghan, Iran.
ORCID-Profile: Mohammad Esmaeil Akbari
Zitieren
APA
Banihashemian, S. S., Akbari, M. E., Pirayesh, E., Divband, G., Abolhosseini Shahrnoy, A., Nami, R., Mazidi, S. M., & Nasiri, M. (2024). Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. European Journal of Nuclear Medicine and Molecular Imaging, 52(1), 237-246. https://doi.org/10.1007/s00259-024-06795-7
Vancouver
Banihashemian SS, Akbari ME, Pirayesh E, Divband G, Abolhosseini Shahrnoy A, Nami R, et al. Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. European Journal of Nuclear Medicine and Molecular Imaging. 2024;52(1):237-246. doi:10.1007/s00259-024-06795-7
BibTeX
@article{Banihashemian2024,
author = {Banihashemian, Seyedeh Somayyeh and Akbari, Mohammad Esmaeil and Pirayesh, Elahe and Divband, Ghasemali and Abolhosseini Shahrnoy, Abdolghafar and Nami, Reza and Mazidi, Seyed Mohammad and Nasiri, Meysam},
title = {Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
volume = {52},
number = {1},
pages = {237--246},
doi = {10.1007/s00259-024-06795-7}
}
EUVIMED